135 related articles for article (PubMed ID: 27102245)
21. Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status.
Manchanda R; Abdelraheim A; Johnson M; Rosenthal AN; Benjamin E; Brunell C; Burnell M; Side L; Gessler S; Saridogan E; Oram D; Jacobs I; Menon U
BJOG; 2011 Jun; 118(7):814-24. PubMed ID: 21392246
[TBL] [Abstract][Full Text] [Related]
22. The lack of clinical value of peritoneal washing cytology in high risk patients undergoing risk-reducing salpingo-oophorectomy: a retrospective study and review.
Blok F; Roes EM; van Leenders GJ; van Beekhuizen HJ
BMC Cancer; 2016 Jan; 16():18. PubMed ID: 26768420
[TBL] [Abstract][Full Text] [Related]
23. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing.
Walsh T; Casadei S; Lee MK; Pennil CC; Nord AS; Thornton AM; Roeb W; Agnew KJ; Stray SM; Wickramanayake A; Norquist B; Pennington KP; Garcia RL; King MC; Swisher EM
Proc Natl Acad Sci U S A; 2011 Nov; 108(44):18032-7. PubMed ID: 22006311
[TBL] [Abstract][Full Text] [Related]
24. Incidental carcinomas in prophylactic specimens in BRCA1 and BRCA2 germ-line mutation carriers, with emphasis on fallopian tube lesions: report of 6 cases and review of the literature.
Carcangiu ML; Peissel B; Pasini B; Spatti G; Radice P; Manoukian S
Am J Surg Pathol; 2006 Oct; 30(10):1222-30. PubMed ID: 17001151
[TBL] [Abstract][Full Text] [Related]
25. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement.
Moyer VA;
Ann Intern Med; 2014 Feb; 160(4):271-81. PubMed ID: 24366376
[TBL] [Abstract][Full Text] [Related]
26. Support of the 'fallopian tube hypothesis' in a prospective series of risk-reducing salpingo-oophorectomy specimens.
Reitsma W; de Bock GH; Oosterwijk JC; Bart J; Hollema H; Mourits MJ
Eur J Cancer; 2013 Jan; 49(1):132-41. PubMed ID: 22921157
[TBL] [Abstract][Full Text] [Related]
27. BRCA2 germline mutations in primary cancer of the fallopian tube.
Casarsa S; Puglisi F; Baudi F; De Paola L; Venuta S; Piga A; Di Loreto C; Marchesoni D; D'Elia AV; Damante G
Oncol Rep; 2004 Aug; 12(2):313-6. PubMed ID: 15254695
[TBL] [Abstract][Full Text] [Related]
28. Risk factors for carcinoma of the fallopian tube in women with and without a germline BRCA mutation.
Vicus D; Finch A; Rosen B; Fan I; Bradley L; Cass I; Sun P; Karlan B; McLaughlin J; Narod SA;
Gynecol Oncol; 2010 Aug; 118(2):155-9. PubMed ID: 20452659
[TBL] [Abstract][Full Text] [Related]
29. Risk factors for non-invasive lesions of the fallopian tube in BRCA mutation carriers.
Vicus D; Shaw PA; Finch A; Rosen B; Murphy J; Armel S; Sun P; Narod SA
Gynecol Oncol; 2010 Sep; 118(3):295-8. PubMed ID: 20722102
[TBL] [Abstract][Full Text] [Related]
30. Timing of referral for genetic counseling and genetic testing in patients with ovarian, fallopian tube, or primary peritoneal carcinoma.
Novetsky AP; Smith K; Babb SA; Jeffe DB; Hagemann AR; Thaker PH; Powell MA; Mutch DG; Massad LS; Zighelboim I
Int J Gynecol Cancer; 2013 Jul; 23(6):1016-21. PubMed ID: 23748176
[TBL] [Abstract][Full Text] [Related]
31. DNA repair mutations and outcomes in ovarian cancer--response.
Swisher EM; Norquist BM; Pennington KP; Rendi MH; Garcia RL
Clin Cancer Res; 2015 Feb; 21(3):659. PubMed ID: 25646182
[No Abstract] [Full Text] [Related]
32. DNA repair mutations and outcomes in ovarian cancer--letter.
Soslow RA
Clin Cancer Res; 2015 Feb; 21(3):658. PubMed ID: 25646181
[No Abstract] [Full Text] [Related]
33. Does the diagnosis of breast or ovarian cancer trigger referral to genetic counseling?
Powell CB; Littell R; Hoodfar E; Sinclair F; Pressman A
Int J Gynecol Cancer; 2013 Mar; 23(3):431-6. PubMed ID: 23354368
[TBL] [Abstract][Full Text] [Related]
34. Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective.
Jarboe EA; Folkins AK; Drapkin R; Ince TA; Agoston ES; Crum CP
Histopathology; 2009 Nov; 55(5):619. PubMed ID: 19912369
[No Abstract] [Full Text] [Related]
35. Preventive gynecologic surgery for BRCA1/2 carriers--information for decision-making.
Quillin JM; Boardman CH; Bodurtha J; Smith T
Gynecol Oncol; 2001 Oct; 83(1):168-70. PubMed ID: 11585435
[No Abstract] [Full Text] [Related]
36. Prevalence of BRCA1 and BRCA2 germ line mutations among women with carcinoma of the fallopian tube.
Vicus D; Finch A; Cass I; Rosen B; Murphy J; Fan I; Royer R; McLaughlin J; Karlan B; Narod SA
Gynecol Oncol; 2010 Sep; 118(3):299-302. PubMed ID: 20570322
[TBL] [Abstract][Full Text] [Related]
37. A genetic epidemiological study of carcinoma of the fallopian tube.
Aziz S; Kuperstein G; Rosen B; Cole D; Nedelcu R; McLaughlin J; Narod SA
Gynecol Oncol; 2001 Mar; 80(3):341-5. PubMed ID: 11263928
[TBL] [Abstract][Full Text] [Related]
38. Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy.
Lamb JD; Garcia RL; Goff BA; Paley PJ; Swisher EM
Am J Obstet Gynecol; 2006 Jun; 194(6):1702-9. PubMed ID: 16731090
[TBL] [Abstract][Full Text] [Related]
39. Occult ovarian cancer at the time of risk-reducing salpingo-oophorectomy.
Powell CB
Gynecol Oncol; 2006 Jan; 100(1):1-2. PubMed ID: 16368438
[No Abstract] [Full Text] [Related]
40. Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers.
Carcangiu ML; Radice P; Manoukian S; Spatti G; Gobbo M; Pensotti V; Crucianelli R; Pasini B
Int J Gynecol Pathol; 2004 Jan; 23(1):35-40. PubMed ID: 14668548
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
